Sign Out
In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence that there is a clinical counterpart of this phenomenon.
In early clinical trials using daily subcutaneous Leuprorelin (Luprolex) in patients with prostate cancer, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose. In cases of overdosage, standard of care monitoring and management principles should be followed.
Continue with Google